InsidersTradesSigma
Follow the Kinnate Biopharma Inc. stock price and the full directors' dealings record of the company, a listed equity based in United States. Shares trade on the US market, under the authority of SEC (Form 4). Operating in the Health Care sector, Kinnate Biopharma Inc. has published 42 reports. The latest transaction was reported on 5 April 2024 (Disposition). Among the most active insiders: Krishnamohan Neha. Every trade is accessible without an account.
42
Insider Decl.
n/a
Thresholds
€12m
9 ops.
Buy Volume
n/a
8 ops.
Sell Volume
43Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 5 April 2024
Declarations42 total
9,671,643 sharesCommon StockSEC:0001104659-24-044187:0
2,186 sharesCommon StockSEC:0001415889-24-010433:0
1,368,339 sharesCommon StockSEC:0000947871-24-000353:0
64,087 sharesCommon StockSEC:0001415889-24-010431:0
1,368,339 sharesCommon StockSEC:0000947871-24-000354:0
27,578 sharesCommon StockSEC:0001415889-24-010424:0
66,377 sharesCommon StockSEC:0001415889-24-010428:0
9,671,643 sharesCommon StockSEC:0001415889-24-010434:0
1,506 shares@ US$2.5910.3% of flowCommon StockSEC:0001415889-24-006755:0
558 shares@ US$2.591.0% of flowCommon StockSEC:0001415889-24-006754:0
558 shares@ US$2.5910.3% of flowCommon StockSEC:0001415889-24-006753:0
1,459 shares@ US$2.258.6% of flowCommon StockSEC:0001209191-23-057455:0
541 shares@ US$2.250.9% of flowCommon StockSEC:0001209191-23-057457:0
541 shares@ US$2.258.6% of flowCommon StockSEC:0001209191-23-057454:0
1,459 shares@ US$2.359.0% of flowCommon StockSEC:0001209191-23-048429:0
541 shares@ US$2.350.9% of flowCommon StockSEC:0001209191-23-048424:0
541 shares@ US$2.359.1% of flowCommon StockSEC:0001209191-23-048426:0
541 shares@ US$4.301.7% of flowCommon StockSEC:0001209191-23-034445:0
541 shares@ US$4.3016.7% of flowCommon StockSEC:0001209191-23-034444:0
1,459 shares@ US$4.3016.7% of flowCommon StockSEC:0001209191-23-034447:0
1,550,956 shares@ US$2.80100.0% of flowCommon StockSEC:0001209191-23-028537:0
Canonical exit: 6 Aug 2023 (T+90)
1,550,956 shares@ US$2.80100.0% of flowCommon StockSEC:0001209191-23-028527:0
Canonical exit: 6 Aug 2023 (T+90)
83,459 shares@ US$2.7511.9% of flowCommon StockSEC:0000947871-23-000540:0
Canonical exit: 2 Aug 2023 (T+90)
83,459 shares@ US$2.7511.9% of flowCommon StockSEC:0000947871-23-000541:0
Canonical exit: 2 Aug 2023 (T+90)
60,998 shares@ US$2.558.1% of flowCommon StockSEC:0000947871-23-000516:0
Canonical exit: 27 Jul 2023 (T+90)
25 of 42 declarations
关于 Kinnate Biopharma Inc.
Kinnate Biopharma Inc. 是一家生物制药公司，专注于开发癌症靶向疗法。该公司采用创新方法来识别和开发满足未满足医疗需求的药物。